DNA cleavage enzymes for treatment of persistent viral infections: Recent advances and the pathway forward

Virology

Volumn 454-455, Issue 1, 2014, Pages 353-361

  Weber, Nicholas D ^a,b   Aubert, Martine ^a   Dang, Chung H ^a   Stone, Daniel ^a   Jerome, Keith R ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Animal models; DNA cleavage enzymes; Endonuclease; Gene therapy; Gene therapy delivery; Persistent viruses; Targeted mutagenesis

Indexed keywords

VIRUS DNA;

BIOLOGICAL MODEL; BIOSAFETY; DNA CLEAVAGE; DNA SEQUENCE; GENETIC ENGINEERING; HEPATITIS B VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T CELL LEUKEMIA VIRUS; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LATENT VIRUS INFECTION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; REVIEW; SKIN EPITHELIUM; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; VIRUS LATENCY; VIRUS REPLICATION; VIRUS STRAIN; WART VIRUS;

ANIMALIA;

ANIMAL MODELS; DNA CLEAVAGE ENZYMES; ENDONUCLEASE; GENE THERAPY; GENE THERAPY DELIVERY; PERSISTENT VIRUSES; TARGETED MUTAGENESIS;

ANIMALS; DNA CLEAVAGE; DNA, VIRAL; HUMANS; VIRUS DISEASES; VIRUS LATENCY; VIRUS PHYSIOLOGICAL PHENOMENA;

EID: 84897961340     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.12.037     Document Type: Review

References (111)

1. Agrawal N., et al. Generation of recombinant skin in vitro by adeno-associated virus type 2 vector transduction. Tissue Eng. 2004, 10(11-12):1707-1715.
2. Akkina R. New generation humanized mice for virus research: comparative aspects and future prospects. Virology 2013, 435(1):14-28.
3. Aubert M., et al. Successful targeting and disruption of an integrated reporter lentivirus using the engineered homing endonuclease Y2 I-AniI. PloS ONE 2011, 6(2):e16825.
4. Aubert M., et al. Inactivation of latent HSV by targeted mutagenesis. Mol. Ther. Nucleic Acids 2014, (in press).
5. Baxter S., et al. Engineering domain fusion chimeras from I-OnuI family LAGLIDADG homing endonucleases. Nucleic Acids Res. 2012, 40(16):7985-8000.
6. Belfort M., Roberts R.J. Homing endonucleases: keeping the house in order. Nucleic Acids Res. 1997, 25(17):3379-3388.
7. Beurdeley M., et al. Compact designer TALENs for efficient genome engineering. Nat. Commun. 2013, 4:1762.
8. Bissig K.D., et al. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J. Clin. Investig. 2010, 120(3):924-930.
9. Bloom K., et al. Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. Mol. Ther. 2013, 21(10):1889-1897.
10. Boissel S., et al. megaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering. Nucleic Acids Res 2013, 10.1093/nar/gkt1224 [Epub ahead of print].
11. Branski L.K., et al. Gene therapy in wound healing: present status and future directions. Gene Ther. 2007, 14(1):1-10.
12. Broker T.R., et al. Viral latency-the papillomavirus model. Dev. Biol. 2001, 106:443-451. (discussion 452-3, 465-75).
13. Buchholz F., Hauber J. In vitro evolution and analysis of HIV-1 LTR-specific recombinases. Methods 2011, 53(1):102-109.
14. Campo M.S. Animal models of papillomavirus pathogenesis. Virus Res. 2002, 89(2):249-261.
15. Carter C.C., et al. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat. Med. 2010, 16(4):446-451.
16. Caspary L., et al. Infections of susceptible and resistant mouse strains with herpes simplex virus type 1 and 2. Arch. Virol. 1980, 65(3-4):219-227.
17. Chen J., et al. An efficient antiviral strategy for targeting hepatitis B virus genome using Transcription Activator-Like Effector Nucleases. Mol. Ther 2013, 10.1038/mt.2013.212 [Epub ahead of print].
18. Chevalier B.S., Stoddard B.L. Homing endonucleases: structural and functional insight into the catalysts of intron/intein mobility. Nucleic Acids Res. 2001, 29(18):3757-3774.
19. Cho S.W., et al. Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res. 2013, 24(1):132-141.
20. Chomont N., et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 2009, 15(8):893-900.
21. Chun T.W., et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997, 387(6629):183-188.
22. Clements J.E., et al. The central nervous system as a reservoir for simian immunodeficiency virus (SIV): steady-state levels of SIV DNA in brain from acute through asymptomatic infection. J. Infect. Dis. 2002, 186(7):905-913.
23. Colleaux L., et al. Universal code equivalent of a yeast mitochondrial intron reading frame is expressed into E. coli as a specific double strand endonuclease. Cell 1986, 44(4):521-533.
24. Cradick T.J., et al. Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol. Ther. 2010, 18(5):947-954.
25. Cradick T.J., et al. CRISPR/Cas9 systems targeting beta-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res. 2013, 41(20):9584-9592.
26. Dandri M., et al. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 2001, 33(4):981-988.
27. Dandri M., et al. Small animal model systems for studying hepatitis B virus replication and pathogenesis. Semin. Liver Dis. 2006, 26(2):181-191.
28. Denton P.W., Garcia J.V. Humanized mouse models of HIV infection. AIDS Rev. 2011, 13(3):135-148.
29. Denton P.W., et al. Generation of HIV latency in humanized BLT mice. J. Virol. 2012, 86(1):630-634.
30. Doorbar J. Latent papillomavirus infections and their regulation. Curr. Opin. Virol. 2013, 3(4):416-421.
31. Dutton J.L., et al. A novel DNA vaccine technology conveying protection against a lethal herpes simplex viral challenge in mice. PloS ONE 2013, 8(10):e76407.
32. Ebina H., et al. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci. Rep. 2013, 3:2510.
33. Finzi D., et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278(5341):1295-1300.
34. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 1999, 5(5):512-517.
35. Fonfara I., et al. Creating highly specific nucleases by fusion of active restriction endonucleases and catalytically inactive homing endonucleases. Nucleic Acids Res. 2012, 40(2):847-860.
36. Frecha C., et al. Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy. Mol. Ther.: J. Am. Soc. Gene Ther. 2010, 18(10):1748-1757.
37. Gagnoux-Palacios L., et al. Assessment of optimal transduction of primary human skin keratinocytes by viral vectors. J. Gene Med. 2005, 7(9):1178-1186.
38. Gaj T., Gersbach C.A., Barbas C.F. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 2013, 31(7):397-405.
39. Gao H., et al. Heritable targeted mutagenesis in maize using a designed endonuclease. The Plant J.:Cell Mol. Biol. 2010, 61(1):176-187.
40. Gebhardt B.M., et al. Animal Models of Ocular Herpes Simplex Virus Infection (Rabbits, Primates, Mice). Handbook of Animal Models of Infection 1999, 919-926. Academic Press, London, UK. M. Sande, O. Zak (Eds.).
41. Glatzel M., et al. Adenoviral and adeno-associated viral transfer of genes to the peripheral nervous system. Proc. Natl. Acad. Sci. USA 2000, 97(1):442-447.
42. Grizot S., et al. Generation of redesigned homing endonucleases comprising DNA-binding domains derived from two different scaffolds. Nucleic Acids Res. 2010, 38(6):2006-2018.
43. Grosse S., et al. Meganuclease-mediated inhibition of HSV1 infection in cultured cells. Mol. Ther. 2011, 19(4):694-702.
44. Guidotti L.G., et al. High-level hepatitis B virus replication in transgenic mice. J. Virol. 1995, 69(10):6158-6169.
45. Guidotti L.G., et al. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999, 284(5415):825-829.
46. Hacein-Bey-Abina S., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302(5644):415-419.
47. Harwood C.A., et al. Increased risk of skin cancer associated with the presence of epidermodysplasia verruciformis human papillomavirus types in normal skin. Br. J. Dermatol. 2004, 150(5):949-957.
48. Hauber I., et al. Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized mice. PLoS Pathog. 2013, 9(9):e1003587.
49. He Z., et al. Liver xeno-repopulation with human hepatocytes in Fah-/-Rag2-/- mice after pharmacological immunosuppression. Am. J. Pathol. 2010, 177(3):1311-1319.
50. Hill J.M., Rayfield M.A., Haruta Y. Strain specificity of spontaneous and adrenergically induced HSV-1 ocular reactivation in latently infected rabbits. Curr. Eye Res. 1987, 6(1):91-97.
51. Hirsch T., et al. Adenoviral gene delivery to primary human cutaneous cells and burn wounds. Mol. Med. 2006, 12(9-10):199-207.
52. Holkers M., et al. Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells. Nucleic Acids Res. 2013, 41(5):e63.
53. Hoshino Y., et al. Rates of reactivation of latent herpes simplex virus from mouse trigeminal ganglia ex vivo correlate directly with viral load and inversely with number of infiltrating CD8+ T cells. J. Virol. 2007, 81(15):8157-8164.
54. Howe S.J., et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 2008, 118(9):3143-3150.
55. Ingle A., et al. Novel laboratory mouse papillomavirus (MusPV) infection. Vet. Pathol. 2011, 48(2):500-505.
56. Jaffe H.A., et al. Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat. Genet. 1992, 1(5):372-378.
57. Joh J., et al. Molecular diagnosis of a laboratory mouse papillomavirus (MusPV). Exp. Mol. Pathol. 2012, 93(3):416-421.
58. Klein E., Kis L.L., Klein G. Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions. Oncogene 2007, 26(9):1297-1305.
59. Knaan-Shanzer S., et al. Highly efficient targeted transduction of undifferentiated human hematopoietic cells by adenoviral vectors displaying fiber knobs of subgroup B. Hum. Gene Ther. 2001, 12(16):1989-2005.
60. Kreider J.W., Bartlett G.L. The Shope papilloma-carcinoma complex of rabbits: a model system of neoplastic progression and spontaneous regression. Adv. Cancer Res. 1981, 35:81-110.
61. Lairmore M.D., et al. Molecular determinants of human T-lymphotropic virus type 1 transmission and spread. Viruses 2011, 3(7):1131-1165.
62. Laycock K.A., et al. Characterization of a murine model of recurrent herpes simplex viral keratitis induced by ultraviolet B radiation. Invest. Ophthalmol. Vis. Sci. 1991, 32(10):2741-2746.
63. Li Q., et al. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum. Gene Ther. 1993, 4(4):403-409.
64. Liu J., et al. Reduction in severity of a herpes simplex virus type 1 murine infection by treatment with a ribozyme targeting the UL20 gene RNA. J. Virol. 2008, 82(15):7467-7474.
65. Maier D.A., et al. Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5. Hum. Gene Ther. 2013, 24(3):245-258.
66. Mali P., et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat. Biotechnol. 2013, 31(9):833-838.
67. Mariyanna L., et al. Excision of HIV-1 proviral DNA by recombinant cell permeable tre-recombinase. PloS ONE 2012, 7(2):e31576.
68. Marsden M.D., et al. HIV latency in the humanized BLT mouse. J. Virol. 2012, 86(1):339-347.
69. Mason M.R., et al. Comparison of AAV serotypes for gene delivery to dorsal root ganglion neurons. Mol. Ther.: J. Am. Soc. Gene Ther. 2010, 18(4):715-724.
70. Mercer D.F., et al. Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 2001, 7(8):927-933.
71. Meuleman P., et al. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology 2005, 41(4):847-856.
72. Miller J.C., et al. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat. Biotechnol. 2007, 25(7):778-785.
73. Mingozzi F., High K.A. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 2013, 122(1):23-36.
74. Mino T., et al. Gene- and protein-delivered zinc finger-staphylococcal nuclease hybrid for inhibition of DNA replication of human papillomavirus. PloS ONE 2013, 8(2):e56633.
75. Moreau A., et al. Efficient intrathymic gene transfer following in situ administration of a rAAV serotype 8 vector in mice and nonhuman primates. Mol. Ther.: J. Am. Soc. Gene Ther. 2009, 17(3):472-479.
76. Nathwani A.C., et al. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood 2006, 107(7):2653-2661.
77. Nathwani A.C., et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 2011, 365(25):2357-2365.
78. Nesburn A.B., Cook M.L., Stevens J.G. Latent herpes simplex virus. Isolation from rabbit trigeminal ganglia between episodes of recurrent ocular infection. Arch. Ophthalmol. 1972, 88(4):412-417.
79. Pandya J., et al. Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy. Immunol. Cell Biol. 2013, 10.1038/icb.2013.74 [Epub ahead of print].
80. Qu X., et al. Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells. Nucleic Acids Res. 2013, 41(16):7771-7782.
81. Ran F.A., et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 2013, 154(6):1380-1389.
82. Raper S.E., et al. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum. Gene Ther. 2002, 13(1):163-175.
83. Raper S.E., et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 2003, 80(1-2):148-158.
84. Rous P., Beard J.W. The progression to carcinoma of virus-induced rabbit papillomas (Shope). J. Exp. Med. 1935, 62(4):523-548.
85. Sarkar I., et al. HIV-1 proviral DNA excision using an evolved recombinase. Science 2007, 316(5833):1912-1915.
86. Sawtell N.M., Thompson R.L. Rapid in vivo reactivation of herpes simplex virus in latently infected murine ganglionic neurons after transient hyperthermia. J. Virol. 1992, 66(4):2150-2156.
87. Sawtell N.M., Thompson R.L. Rapid in vivo reactivation of herpes simplex virus in latently infected murine ganglionic neurons after transient hyperthermia. J. Virol. 1992, 66(4):2150-2156.
88. Schiffer J.T., et al. Targeted DNA mutagenesis for the cure of chronic viral infections. J. Virol. 2012, 86(17):8920-8936.
89. Schroers R., et al. Gene transfer into human T lymphocytes and natural killer cells by Ad5/F35 chimeric adenoviral vectors. Exp. Hematol. 2004, 32(6):536-546.
90. Scriba M. Persistence of herpes simplex virus (HSV) infection in ganglia and peripheral tissues of guinea pigs. Med. Microbiol. Immunol. 1981, 169(2):91-96.
91. Scriba M., Tatzber F. Pathogenesis of herpes simplex virus infections in guinea pigs. Infect. Immun. 1981, 34(3):655-661.
92. Segal D.J., et al. Toward controlling gene expression at will: selection and design of zinc finger domains recognizing each of the 5'-GNN-3' DNA target sequences. Proc. Natl. Acad. Sci. USA 1999, 96(6):2758-2763.
93. + T cells. Nat. Med. 2003, 9(6):727-728.
94. Sinclair J. Human cytomegalovirus: latency and reactivation in the myeloid lineage. J. Clin. Virol.: Off. Publ. Pan Am. Soc. Clin. Virol. 2008, 41(3):180-185.
95. Sollu C., et al. Autonomous zinc-finger nuclease pairs for targeted chromosomal deletion. Nucleic Acids Res. 2010, 38(22):8269-8276.
96. Stoddart C.A., et al. Superior human leukocyte reconstitution and susceptibility to vaginal HIV transmission in humanized NOD-scid IL-2Rgamma(-/-) (NSG) BLT mice. Virology 2011, 417(1):154-160.
97. Stone D., Kiem H.P., Jerome K.R. Targeted gene disruption to cure HIV. Curr. Opin. HIV AIDS 2013, 8(3):217-223.
98. Strain M.C., et al. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc. Natl. Acad. Sci. USA 2003, 100(8):4819-4824.
99. Streubel J., et al. TAL effector RVD specificities and efficiencies. Nat. Biotechnol. 2012, 30(7):593-595.
100. Szczepek M., et al. Structure-based redesign of the dimerization interface reduces the toxicity of zinc-finger nucleases. Nat. Biotechnol. 2007, 25(7):786-793.
101. Tanaka A., et al. A novel therapeutic molecule against HTLV-1 infection targeting provirus. Leukemia 2013, 27(8):1621-1627.
102. Terashima T., et al. DRG-targeted helper-dependent adenoviruses mediate selective gene delivery for therapeutic rescue of sensory neuronopathies in mice. J. Clin. Investig. 2009, 119(7):2100-2112.
103. Thompson K.A., et al. Brain cell reservoirs of latent virus in presymptomatic HIV-infected individuals. Am. J. Pathol. 2011, 179(4):1623-1629.
104. Tsuge M., et al. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology 2005, 42(5):1046-1054.
105. Veldwijk M.R., et al. Pseudotyped recombinant adeno-associated viral vectors mediate efficient gene transfer into primary human CD34(+) peripheral blood progenitor cells. Cytotherapy 2010, 12(1):107-112.
106. Wadman M. Chimp research under scrutiny. Nature 2011, 480(7378):424-425.
107. Walter E., et al. Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo. Hepatology 1996, 24(1):1-5.
108. Wang K., et al. Laser-capture microdissection: refining estimates of the quantity and distribution of latent herpes simplex virus 1 and varicella-zoster virus DNA in human trigeminal ganglia at the single-cell level. J. Virol. 2005, 79(22):14079-14087.
109. Wang K., et al. Diverse herpes simplex virus type 1 thymidine kinase mutants in individual human neurons and ganglia. J. Virol. 2007, 81(13):6817-6826.
110. Wong J.K., et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278(5341):1291-1295.
111. Yu H., et al. Lentiviral gene transfer into the dorsal root ganglion of adult rats. Mol. Pain 2011, 7:63.